Loading company…
San Francisco biopharmaceutical company developing enzyme replacement therapies for rare neurological disorders such as MPS IIIB.
Established in 2016 and headquartered in San Francisco, US, Spruce Biosciences, Inc. develops therapies for rare neurological disorders. Its lead product, Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT), targets Mucopolysaccharidosis Type IIIB (MPS IIIB). CEO Javier Szwarcberg leads the company, and in January 2026 it raised USD 15 million in venture debt from Avenue Capital.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in